

Göttingen, Germany | March 27, 2025

Sartorius AG - Resolutions of the Annual General Meeting

The life science group Sartorius held its virtual Annual General Meeting today. The shareholders approved all proposals of the Supervisory Board and the Executive Board by a large majority, including the dividend proposal of 0.74 euros per preference share and 0.73 euros per ordinary share. The total amount disbursed will be 50.7 million euros, with the dividend to be paid out to shareholders on April 1, 2025.

Further information

[Website Annual General Meeting](#)

[Image files](#)

[CVs and images of Executive Board and Supervisory Board](#)

Financial calendar

April 16, 2025	Publication of the first quarter results January to March 2025
July 22, 2025	Publication of the half-year results January to June 2025
October 16, 2025	Publication of the nine-month results January to September 2025

A profile of Sartorius

Sartorius is a leading international partner of life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services Division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions Division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies safely, rapidly, and sustainably. The company, based in Göttingen, Germany, has a strong global reach with around 60 production and sales sites worldwide. Sartorius regularly expands its portfolio through the acquisition of complementary technologies. In 2024, the company generated sales revenue of around 3.4 billion euros. Around 13,500 employees are working for customers around the globe.

Visit our [Newsroom](#) and follow Sartorius on [LinkedIn](#).

Contact

Leona Malorny
Head of External Communications
+49 551 308 4067
leona.malorny@sartorius.com